Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status
Cancers · 10.02.2024 · 16 (4) · 738
DOI: 10.3390/cancers16040738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 10.02.2024. Verfasst von Anna Maria Hage und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universitä…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Data are scarce on the role of pathogenic germline variants in BRCA1 and BRCA2 (gBRCAm) in subtype-specific survival in young women who develop breast cancer under the age of 40. This retrospective, real-world cohort study assessed the distant disease-free survival (DDFS) and overall survival (OS) of young women diagnosed with breast cancer between 2008 and 2019 while taking into consideration the interaction of clinical subtypes and the gBRCA status. Among 473 women, HR+/Her2− was the most common subtype (49.0%), followed by TNBC (31.3%), HR+/Her2+ (13.7%), and Her2+/HR− (5.9%). The gBRCA status was known for 319 cases (gBRCAwt (wild-type – without pathogenic variants in BRCA1 or BRCA2): 204, gBRCA1m: 83, gBRCA2m: 31, 1 patient with both). The distribution of clinical subtypes varied depending on the gBRCA status (p < 0.001). In survival analysis with a median follow-up of 43 months, the unadjusted DDFS and OS were worse for gBRCAwt TNBC compared to both HR+ subtypes, but not for gBRCAm TNBC patients. T-stage, nodal involvement, and the gBRCA status were identified as significant for survival in TNBC. In TNBC, gBRCAm was associated with better DDFS and OS than gBRCAwt (5-year DDFS 81.4% vs. 54.3%, p = 0.012 and 5-year OS 96.7% vs. 62.7%, p < 0.001). In contrast, in HR+/Her2− patients, gBRCAm patients showed a tendency for worse survival, though not statistically significant. Subtype-specific survival in young women with breast cancer needs to be evaluated in interaction with the gBRCA status. For TNBC, gBRCAm is of favorable prognostic value for overall survival, while patients with gBRCAwt TNBC need to be considered to have the highest risk for adverse survival outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, 10117 Berlin, Germany.
- Institute of Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, 10117 Berlin, Germany.
- Department of Oncology-Pathology, Karolinska Comprehensive Cancer Centre, 17176 Stockholm, Sweden.
ORCID-Profile: Anna Maria Hage, Pimrapat Gebert, Jens-Uwe Blohmer, Elham Hedayati, Maria Margarete Karsten
Zitieren
APA
Hage, A. M., Gebert, P., Blohmer, J. U., Hedayati, E., Speiser, D., & Karsten, M. M. (2024). Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status. Cancers, 16(4), 738. https://doi.org/10.3390/cancers16040738
Vancouver
Hage AM, Gebert P, Blohmer JU, Hedayati E, Speiser D, Karsten MM. Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status. Cancers. 2024;16(4):738. doi:10.3390/cancers16040738
BibTeX
@article{Hage2024,
author = {Hage, Anna Maria and Gebert, Pimrapat and Blohmer, Jens-Uwe and Hedayati, Elham and Speiser, Dorothee and Karsten, Maria Margarete},
title = {Subtype-Specific Survival of Young Women with Breast Cancer and Its Interaction with the Germline BRCA Status},
journal = {Cancers},
year = {2024},
volume = {16},
number = {4},
pages = {738},
doi = {10.3390/cancers16040738}
}
EUVIMED